Ascendis Pharma Shares Surge Amid Optimistic 2026 Projections and Market Expansion Plans
Ascendis Pharma's stock climbed to a record level following RBC Capital's upgraded price target, reflecting strong expectations for the company's key drug Yorvipath and promising international market opportunities. The company highlighted sustained patient growth, a relatively untapped U.S. market, and significant European potential, accompanied by…